• Careers
  • Support
Clusters of blue and green exosomes.

On the Edge of the Bubble: Use of Exosomes as Reference Materials in Biomedical Research

October 31, 2019, at 12:00 PM ET


Exosomes are membrane vesicles that are secreted by cells into the surrounding environment to mediate intercellular communication. Because exosomes from diseased individuals can exhibit different molecular profiles from their normal counterparts, they are an attractive target for the development of diagnostic tests. Alternatively, exosomes could be used to develop novel drug delivery systems due to their intrinsic transport function. However, a major drawback for scientists is that isolating a consistent population of exosomes is challenging, and there is a marked lack of exosome standards with confirmed, well-defined characteristics. In this presentation, we provide an overview of exosomes from various well-characterized ATCC cell lines, and show data indicating that these extracellular vesicles can be used as reference materials in biological research and assay development.

Key Points

  • There is an unmet need for well-characterized exosome reference materials.
  • Exosomes from ATCC cells can serve as consistent, natural standards for molecular assay development or utilized to develop novel drug delivery systems.
  • ATCC experts generated characterization and application data indicating that exosomes can be implemented in multiple functional assays.

Watch The Presentation


Siddhartha Paul, headshot.

Siddhartha Paul, PhD

Scientist, ATCC

Siddhartha Paul, PhD, is a scientist at ATCC whose research focuses on the use of emerging and novel technologies in the development of advanced models for cell biology. He currently serves as a subject matter expert on exosomes and extracellular vesicles, and he is working toward the development of research tools and reagents for exosome research. Previously, he worked at the Lombardi Cancer Research Center at Georgetown University, where his research focused on developing culture models from HPV-induced tumors using novel conditional reprograming technology. Dr. Paul obtained his PhD in Biochemistry from Ruhr University Bochum in Germany.